Norman Wolmark
#102,831
Most Influential Person Now
Norman Wolmark's AcademicInfluence.com Rankings
Norman Wolmarkphysics Degrees
Physics
#3583
World Rank
#5056
Historical Rank
Cosmology
#92
World Rank
#97
Historical Rank
Astrophysics
#180
World Rank
#197
Historical Rank

Download Badge
Physics
Norman Wolmark's Degrees
- Bachelors Physics University of California, Berkeley
- Masters Physics University of California, Berkeley
- PhD Physics University of California, Berkeley
Why Is Norman Wolmark Influential?
(Suggest an Edit or Addition)Norman Wolmark's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
- A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. (2004) (5593)
- Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. (1999) (5389)
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. (2005) (5306)
- Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) (2895)
- Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. (2006) (2385)
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. (1998) (2102)
- Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. (1985) (2054)
- Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. (1997) (1718)
- Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006) (1594)
- Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. (1989) (1558)
- Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. (2008) (1548)
- A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. (1989) (1427)
- Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. (2010) (1366)
- Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. (1985) (1318)
- Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. (2002) (1271)
- Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. (2005) (1251)
- Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. (2002) (1239)
- Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. (2001) (1237)
- Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer (2019) (1209)
- Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. (1995) (1131)
- The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. (2003) (1080)
- Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. (1988) (1003)
- Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial (1999) (985)
- Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. (2007) (954)
- Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. (2007) (909)
- Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. (2006) (907)
- Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. (1996) (884)
- Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. (2009) (835)
- Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. (1993) (821)
- Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. (2005) (776)
- Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. (2001) (751)
- Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. (2014) (741)
- 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. (1975) (704)
- Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. (2005) (695)
- Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. (2011) (685)
- Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. (2011) (680)
- erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. (1998) (674)
- The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. (1993) (656)
- Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. (1998) (637)
- Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. (2001) (637)
- Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. (2004) (632)
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer (2010) (594)
- Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe (1990) (593)
- Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. (2011) (576)
- Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. (2002) (574)
- Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. (2011) (557)
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
- Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. (2010) (543)
- Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) (1999) (536)
- Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. (2001) (518)
- Significance of ipsilateral breast tumour recurrence after lumpectomy (1991) (517)
- Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. (1997) (512)
- Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. (2000) (506)
- Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. (2002) (492)
- Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. (2005) (488)
- Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. (1999) (469)
- Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. (2012) (457)
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. (2018) (443)
- The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. (1994) (437)
- Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. (2006) (433)
- Bevacizumab added to neoadjuvant chemotherapy for breast cancer. (2012) (432)
- The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. (1981) (431)
- Morbidity results from the NSABP B‐32 trial comparing sentinel lymph node dissection versus axillary dissection (2010) (424)
- Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. (2004) (421)
- Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. (2009) (400)
- Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. (1988) (399)
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. (2021) (398)
- A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum (1997) (384)
- A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. (1989) (379)
- Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. (1975) (365)
- CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. (2016) (362)
- Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. (2004) (359)
- Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. (2014) (354)
- Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials (2004) (348)
- Pathobiology of preoperative chemotherapy (2002) (338)
- Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. (2007) (332)
- Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. (2006) (331)
- Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. (2013) (327)
- Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. (1997) (325)
- HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. (2000) (322)
- Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. (2006) (317)
- Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. (2003) (313)
- Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. (2008) (310)
- Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. (2010) (305)
- Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. (1990) (302)
- Treatment of primary breast cancer with chemotherapy and tamoxifen. (1981) (296)
- Effect of occult metastases on survival in node-negative breast cancer. (2011) (285)
- Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer (2012) (284)
- Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. (2010) (277)
- Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. (1983) (274)
- Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value (2012) (272)
- Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. (2001) (260)
- Interstitial hypertension in human breast and colorectal tumors. (1992) (259)
- Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. (2002) (250)
- Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. (2009) (248)
- Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006) (247)
- Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. (2015) (245)
- Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer (2007) (232)
- Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial (2019) (230)
- Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. (1999) (226)
- Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. (2007) (226)
- Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and (1996) (226)
- The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. (2011) (211)
- Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. (1986) (209)
- The Prognostic Value of the Modifications of the Dukes' C Class of Colorectal Cancer: An Analysis of the NSABP Clinical Trials (1986) (208)
- Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. (1990) (204)
- Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. (2012) (200)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Association of tamoxifen and uterine sarcoma. (2002) (196)
- Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). (2017) (196)
- Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20 (2011) (191)
- Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. (2013) (184)
- A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07 (2005) (173)
- Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. (2012) (166)
- Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. (2014) (165)
- The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. (1983) (164)
- The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. (1984) (164)
- Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (2004) (163)
- Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. (2013) (154)
- Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. (2010) (154)
- An Analysis of Survival and Treatment Failure Following Abdominoperineal and Sphincter‐saving Resection in Dukes' B and C Rectal Carcinoma: A Report of the NSABP Clinical Trials (1986) (152)
- Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. (1989) (151)
- Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. (2016) (149)
- Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. (2001) (144)
- HER2 status and benefit from adjuvant trastuzumab in breast cancer. (2008) (144)
- Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. (2012) (142)
- NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. (2019) (141)
- Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial (2016) (137)
- Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. (1999) (133)
- Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. (2015) (131)
- Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. (2011) (129)
- A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. (2009) (129)
- Eight-year Results of a Randomized Clinical Trial Comparing Total Mastectomy and Lumpectomy with or without Irradiation in the Treatment of Breast Cancer (1989) (128)
- NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: A description of the trial (2004) (125)
- Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. (2011) (122)
- Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. (2013) (121)
- Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. (1987) (117)
- Long-term tamoxifen citrate use and potential ocular toxicity. (1998) (114)
- Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer (2009) (114)
- Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. (2011) (113)
- Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. (1998) (112)
- The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy (2003) (111)
- Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. (2019) (110)
- Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. (2001) (110)
- Long-Term Survival Results of Surgery Alone Versus Surgery Plus 5-Fluorouracil and Leucovorin for Stage II and Stage III Colon Cancer: Pooled Analysis of NSABP C-01 Through C-05. A Baseline from Which to Compare Modern Adjuvant Trials (2010) (109)
- Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. (2015) (107)
- Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial (2008) (104)
- Body Mass Index and the Risk for Developing Invasive Breast Cancer among High-Risk Women in NSABP P-1 and STAR Breast Cancer Prevention Trials (2012) (103)
- 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy (2017) (103)
- Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer (2005) (102)
- Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. (2013) (101)
- OT2-06-02: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women with Stage 0, 1, or 2 Breast Cancer: NSABP B-39/RTOG 0413. (2011) (100)
- A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. (2009) (99)
- Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (99)
- Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. (2004) (99)
- Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. (2006) (97)
- Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. (2011) (95)
- Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma (2005) (95)
- Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. (2011) (91)
- Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. (2005) (89)
- The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. (2002) (88)
- Multi-gene Rt-pcr assay for predicting recurrence in node negative breast cancer patients-nsabp studies B-20 and B-14 (2003) (87)
- Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. (2010) (86)
- Long‐term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C‐07 and LTS‐01 (2012) (83)
- Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. (2003) (82)
- Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
- Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial (2017) (81)
- Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. (2018) (81)
- Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)->paclitaxel (T) vs. AC->T with trastuzumab (H) (2006) (81)
- Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. (2004) (80)
- A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. (2009) (80)
- Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer (2013) (79)
- Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. (2001) (75)
- Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31 (2007) (75)
- Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. (2009) (74)
- Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) (74)
- Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. (2007) (74)
- Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials (2008) (72)
- Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer. (2002) (72)
- Lower-category benign breast disease and the risk of invasive breast cancer. (2004) (71)
- Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. (2010) (70)
- Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). (2006) (69)
- Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. (2007) (67)
- Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Proje (2016) (67)
- Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial (2016) (66)
- FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer (2008) (66)
- Amenorrhea from breast cancer therapy--not a matter of dose. (2010) (66)
- Tumor size and regional lymph node metastasis in colorectal cancer a preliminary analysis from the NSABP clinical trials (1983) (66)
- Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43 (2013) (65)
- A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. (2010) (65)
- Health-Related Quality of Life in Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer Patients Undergoing AC Versus CMF Chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23 (2004) (65)
- Inhibitory effect of prolonged corynebacterium parvum and cyclophosphamide administration on the growth of established tumors (1975) (63)
- Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. (2013) (63)
- Dukes' classification revisited. Findings from the national surgical adjuvant breast and bowel projects (protocol r‐01) (1989) (62)
- Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study (2013) (60)
- Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. (2010) (60)
- Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women (2008) (59)
- 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer (2018) (58)
- Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. (2013) (58)
- Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. (2011) (57)
- Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial. (2020) (56)
- Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials (2011) (55)
- Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. (2006) (55)
- Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer. (1999) (54)
- The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice. (1974) (54)
- Thermal expansion measurements of frozen biological tissues at cryogenic temperatures. (1998) (54)
- Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. (2019) (52)
- Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. (2012) (52)
- Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience. (1986) (52)
- Role of anthracyclines in the treatment of early breast cancer. (2009) (51)
- Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers. (2001) (50)
- Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials. (2003) (49)
- Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. (2004) (48)
- Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. (2020) (48)
- Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. (2021) (48)
- Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04. (2015) (47)
- Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. (1998) (47)
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial (2006) (46)
- Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831 (2012) (46)
- Letrozole after tamoxifen for breast cancer--what is the price of success? (2003) (46)
- Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. (2000) (46)
- Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies (2019) (46)
- Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? (2012) (46)
- Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials. (1989) (45)
- 10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. (2010) (45)
- Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. (2019) (44)
- A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06 (2004) (44)
- Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group (2009) (44)
- Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5‐fluorouracil/leucovorin plus or minus oxaliplatin (2007) (42)
- Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (42)
- Lower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer (2004) (42)
- National Surgical Adjuvant Breast and Bowel Project trials in colon cancer. (2001) (42)
- Abstract GS4-04: Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer (2019) (42)
- Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. I. Variation in administration of both agents. (1975) (39)
- Residence time distributions of various tracers in tumors: implications for drug delivery and blood flow measurement. (1994) (38)
- An experimental study of the mechanical response of frozen biological tissues at cryogenic temperatures. (1996) (38)
- CDX 2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer (2016) (37)
- Long-term follow-up post-cryosurgery in a sheep breast model. (1999) (37)
- Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52 (2017) (37)
- Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum. (2004) (36)
- Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38 (2015) (36)
- Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database. (2020) (36)
- NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. (2009) (35)
- The Prognostic Significance of Tumor Location and Bowel Obstruction in Dukes B and C Colorectal Cancer (1983) (34)
- Endogenous sex hormone levels and breast cancer risk (1987) (34)
- Is Sentinel Node Biopsy Necessary in Conservatively Treated DCIS? (2007) (34)
- Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE. (2021) (33)
- A comparison of stapled and handsewn anastomoses in patients undergoing resection for Dukes' B and C colorectal cancer (1986) (32)
- Dukes' classification revisited. Findings from the National Surgical Adjuvant Breast and Bowel Projects (Protocol R-01). (1989) (32)
- The use of tamoxifen and raloxifene for the prevention of breast cancer. (2009) (32)
- 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology (2018) (32)
- Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum (2004) (32)
- Status of adjuvant therapy for colorectal cancer. (1989) (31)
- The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in normal mice. (1974) (31)
- Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28. (2012) (30)
- Gross damage accumulation on frozen rabbit liver due to mechanical stress at cryogenic temperatures. (1997) (30)
- Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). (2017) (30)
- Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0) (2007) (29)
- Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer. (2019) (29)
- Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents. (1981) (29)
- Delayed severe hypertriglyceridemia from tamoxifen. (1997) (28)
- Neoadjuvant rectal cancer (RC) score to predict survival: Potential surrogate endpoint for early-phase trials. (2014) (28)
- Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). (2011) (27)
- Evaluation of the worth of Corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer: Eight‐year results from the national surgical adjuvant breast and bowel project B‐10 (1990) (27)
- Survival after IBTR in NSABP Node Negative Protocols B-13, B-14, B-19, B-20 and B-23 (2005) (27)
- Conservative surgery: the American experience. (1986) (27)
- Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a Prospective Randomized Trial Evaluating Chemotherapy after Local Therapy for Isolated Locoregional Recurrences of Breast Cancer (2008) (27)
- Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. (2010) (26)
- The effect of Corynebacterium parvum in combination with 5-fluorouracil, L-phenylalanine mustard, or methotrexate on the inhibition of tumor growth. (1976) (26)
- Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). (2014) (26)
- Neoadjuvant therapy for rectal cancer: Mature results from NSABP protocol R-04. (2014) (26)
- Lumpectomy and axillary dissection for breast cancer: Surgical, pathological, and radiation considerations (1985) (25)
- Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer (2008) (25)
- Baseline Mammographic Breast Density and the Risk of Invasive Breast Cancer in Postmenopausal Women Participating in the NSABP Study of Tamoxifen and Raloxifene (STAR) (2012) (25)
- Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. (2005) (25)
- The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. (2011) (25)
- A phase II clinical trial of ZD1839 (Iressa™) in combination with docetaxel as first-line treatment in patients with advanced breast cancer (2007) (25)
- S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis. (2011) (25)
- Response to "Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation" (Int J Radiat Oncol Biol Phys 2010;76:71-78) and "Toxicity of three-dimensional conformal radiotherapy for accelerated partial bre (2010) (25)
- A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. (2008) (25)
- Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab (H). (2006) (25)
- An Association Between Postoperative Radiotherapy for Primary Breast Cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) Studies and the Subsequent Appearance of Pleural Mesothelioma (2007) (24)
- Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches. (2007) (24)
- NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—First experimental arm (EA) initial results. (2019) (24)
- NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (2019) (24)
- Abstract S1-10: Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): Results from NSABP B-28 (2012) (23)
- Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial (2017) (23)
- Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. (2021) (23)
- Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative br (2016) (23)
- Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination (2019) (22)
- Effect of Corynebacterium parvum on cytotoxicity of regional and nonregional lymph node cells from animals with tumors present or removed. (1974) (22)
- Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. (2011) (22)
- Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. (2020) (22)
- The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer. (2011) (22)
- Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. III. Effect of C. parvum on cyclophosphamide metabolism. (1976) (22)
- Is boost therapy necessary in the treatment of DCIS (2008) (21)
- Final results from NSABP protocol R-04: Neoadjuvant chemoradiation (RT) comparing continuous infusion (CIV) 5-FU with capecitabine (Cape) with or without oxaliplatin (Ox) in patients with stage II and III rectal cancer. (2014) (21)
- A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2 (2015) (21)
- National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities (2013) (20)
- Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32. (2012) (20)
- Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy. (2016) (20)
- The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study. (2006) (20)
- Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. (2020) (20)
- A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Results of NSABP C-10. (2010) (20)
- Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox). (2012) (20)
- Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41. (2016) (19)
- The Prognostic Significance of Preoperative Carcinoembryonic Antigen Levels in Colorectal Cancer: Results from NSABP Clinical Trials (1984) (19)
- Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. (2015) (19)
- Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9 (2015) (18)
- Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer (2015) (18)
- A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06. (2004) (17)
- Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. (2010) (17)
- Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue. (2006) (17)
- Correlation of antitumor chemoimmunotherapy with bone marrow macrophage precursor cell stimulation and macrophage cytotoxicity. (1976) (17)
- Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score. (2010) (16)
- Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) → docetaxel (T) arm of NSABP B-30: Preliminary results (2005) (16)
- Non-invasive breast carcinoma (2005) (16)
- Surgeon training, protocol compliance, and technical outcomes from breast cancer sentinel lymph node randomized trial. (2009) (16)
- Adjuvant chemotherapy in colorectal cancer. (1985) (15)
- Predictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trial. (2016) (15)
- Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02) (2012) (15)
- The effect of a growing tumor and its removal on the cytotoxicity of macrophages from cultured bone marrow cells. (1976) (14)
- Further observations on the inhibition of tumor growth by corynebacterium parvum with cyclophosphamide. (1976) (14)
- Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study (2014) (14)
- The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project. (2008) (14)
- NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (2012) (14)
- NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. (2018) (13)
- Predictive Biomarkers and Personalized Medicine MutationPro fi ling andMicrosatellite Instability in Stage II and III Colon Cancer : An Assessment of Their Prognostic and Oxaliplatin Predictive Value (2012) (13)
- The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. (2011) (13)
- Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial (2021) (13)
- Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42. (2021) (13)
- Predictive value of microsatellite instability-high remains controversial. (2007) (13)
- Abstract 2837: A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+ breast cancer (2015) (12)
- Overall survival (OS) and updated disease-free survival (DFS) results of the NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer. (2011) (12)
- Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. II. Effect of cortisone acetate. (1976) (12)
- Abstract S2-05: 10-yr follow-up results of occult detected sentinel node disease: NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients (2013) (12)
- A phase I dose-escalation study evaluating weekly paclitaxel with neratinib and trastuzumab in women with metastatic HER2-positive breast cancer, NSABP FB-8. (2012) (12)
- NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—Pembrolizumab experimental arm (EA) primary results. (2021) (12)
- Minimal breast cancer: advance or anachronism? (1985) (12)
- Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach. (2010) (12)
- Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. (2021) (12)
- A compact cryosurgical apparatus for minimally invasive procedures. (1997) (12)
- NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC->paclitaxel (P) plus gemcitabine (G) with DD AC->P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. (2012) (11)
- Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer (2020) (11)
- Development of a cryosurgical technique for breast malignancies (1999) (11)
- Sam Wieand, PhD (2006) (11)
- Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen. (2014) (10)
- IS TAMOXIFEN A RISK FACTOR FOR RETINAL VASO-OCCLUSIVE DISEASE? (2005) (10)
- Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study (2020) (10)
- Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803. (2009) (10)
- Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40 (2015) (10)
- Update on design of the National Surgical Adjuvant Breast and Bowel Project trial R-04. (2005) (10)
- Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. (2008) (9)
- Abstract OT1-1-06: A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE) (2013) (9)
- Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction-benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer). (2019) (9)
- Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF 423 Regulation of BRCA 1 Expression : Individualized Breast Cancer Prevention (2013) (9)
- Long-term outcomes after invasive breast tumor recurrence (IBTR) in women with DCIS in NSABP B-17 and B-24 (2007) (9)
- NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response (2020) (9)
- The clinical significance of thymidylate synthase (TS) expression in primary colorectal cancer: An Intergroup combined analysis (2005) (9)
- Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial. (2021) (8)
- NSABP Protocol B-06: A randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer — Results after 15 years of follow-up (1998) (8)
- NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer. (2020) (8)
- NRG-GI002: A phase II clinical trial platform for total neoadjuvant therapy (TNT) in rectal cancer. (2017) (8)
- Conditional survival for patients with colon cancer: An analysis of National Surgical Adjuvant Breast and Bowel Project (NSABP) trials C-03 through C-06. (2006) (8)
- The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40 (2017) (8)
- Milestone clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). (2017) (8)
- Results of Investigations with Corynebacterium parvum in an Experimental Animal System (1975) (8)
- Surgery in the primary treatment of breast cancer (2005) (8)
- Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA). (2020) (7)
- Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. (2019) (7)
- The study of tamoxifen and raloxifene (STAR): First report of patient-reported outcomes (PROs) from the NSABP P-2 Breast Cancer Prevention Study. (2006) (7)
- Future directions in the adjuvant treatment of colon cancer. (1997) (7)
- Limited surgical management for primary breast cancer: A commentary on the NSABP reports (1985) (7)
- The treatment of patients with melanoma using interleukin-2, interleukin-4 and tumor infiltrating lymphocytes. (1992) (7)
- Durable improvement in disease-free survival (DFS) and overall survival (OS) for stage II or III colon cancer treated with leucovorin-modulated fluorouracil (FL): 10-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol C-03 (2005) (7)
- Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC). (2014) (7)
- Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database. (2019) (7)
- What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report (2020) (7)
- Chemoimmunotherapy of metastatic murine renal cell carcinoma using flavone acetic acid and interleukin 2. (1992) (7)
- Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. (2019) (6)
- Effect of body mass index on outcomes in patients with Dukes B and C colon cancer: An analysis of NSABP randomized trials (2005) (6)
- NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer. (2013) (6)
- Adjuvant therapy in primary breast cancer. (1985) (6)
- Adjuvant tamoxifen and chemotherapy in stage II breast cancer: Interim findings from NSABP protocol B-09 (1985) (6)
- Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer. (2015) (6)
- P39 08 TP – INTERSTITIAL HYPERTENSION IN HUMAN PRIMARY AND METASTATIC TUMORS (1991) (6)
- Abstract P3-11-02: Breast cancer-specific mortality (BCSM) in patients (pts) with node-negative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: A SEER-genomic population-based study (2019) (6)
- Adjuvant therapy for colorectal cancer: the NSABP clinical trials. (1988) (6)
- Systemic Adjuvant (Combined Modality) Therapy in the Treatment of Primary Breast Cancer (1977) (5)
- Primary results of NRG Oncology / NSABP B-43: Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT) with RT alone for women with HER2-positive ductal carcinoma in situ (DCIS) after lumpectomy. (2020) (5)
- Correlations Among p 53 , Her-2 / neu , and ras Overexpression and Aneuploidy by Multiparameter Flow Cytometry in Human Breast Cancer : Evidence for a Common Phenotypic Evolutionary Pattern in Infiltrating Ductal Carcinomas 1 (2000) (5)
- NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instabili (2021) (5)
- Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. (2020) (5)
- Laminated Marlex-methyl methacrylate prosthesis for massive chest wall resection. (1980) (5)
- Outcomes in white (W) patients (pts) and those of African (A) descent receiving adjuvant therapy for colon cancer (CC) (2007) (5)
- Adjuvant chemotherapy in stage-II breast cancer: An overview of the NSABP clinical trials (2005) (5)
- PD07-08: The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy: NSABP Protocol B-40. (2011) (5)
- Genetic Variant Associated with Survival of Patients with Stage II-III Colon Cancer. (2019) (5)
- Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database. (2018) (5)
- Adjuvant chemotherapy in stage II breast cancer: A brief overview of the NSABP clinical trials (1985) (5)
- Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield (1993) (5)
- Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metas (2021) (5)
- NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. (2009) (5)
- Use of a prognostic (prog) gene index and nodal status to identify a subset of stage II and III colon cancer patients (pts) who may not need oxaliplatin (ox)-containing adjuvant chemotherapy. (2010) (5)
- NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer. (2018) (5)
- Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial. (2018) (5)
- OT1-02-05: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy to Radiation Therapy (RT) Alone for Women with HER2−Positive DCIS Resected by Lumpectomy: NSABP B-43. (2011) (4)
- Indications for breast-preserving surgery and adjuvant therapy in early breast cancer. (1994) (4)
- Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29 (2015) (4)
- EVALUATION OF POST CRYOSURGERY INJURY IN A SHEEP BREAST MODEL USING THE VITAL STAIN 2,3,5-TRIPHENYLTETRAZOLIUM CHLORIDE (1998) (4)
- Re-Evaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. (2021) (4)
- Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (2019) (4)
- Patient-reported outcomes (PROs) comparison of 5-FU and capecitabine (cape) with concurrent radiotherapy (RT) for neoadjuvant treatment of rectal cancer: Results of NSABP R-04. (2012) (4)
- NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC). (2018) (4)
- Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients. (2021) (4)
- Factors associated with participant adherence in the NSABP Study of Tamoxifen and Raloxifene (STAR) (2008) (4)
- Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2-negative locally advanced breast cancer (LABC): A phase II trial of the NSABP (2009) (4)
- Bernard Fisher, 1918-2019. (2020) (4)
- Abstract P6-07-01: Prognostic impact of the 21-gene Recurrence Score (RS) on loco-regional recurrence (LRR) of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28 (2012) (4)
- Pattern of regional failure in patients with breast cancer treated by lumpectomy, breast radiation +/− chemotherapy and/or tamoxifen with no regional radiation: results from 10 NSABP randomized trials (2003) (4)
- MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice (2021) (4)
- The current status of systemic adjuvant therapy in the management of primary breast cancer. (1981) (4)
- A comparison of quality of life in colon cancer patients receiving adjuvant uracil/ftorafur + leucovorin versus 5-fluorouracil + leucovorin in NSABP C-06 (2005) (4)
- Current Activities of the Coalition of Cancer Cooperative Groups. (2018) (4)
- NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx). (2013) (4)
- Chemotherapy and tamoxifen for breast cancer. (1981) (3)
- Abstract PD05-02: Genome-Wide Associations of Breast Events and Functional Genomic Studies in High-Risk Women Receiving Tamoxifen or Raloxifene on NSABP P1 and P2 Prevention Trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration (2010) (3)
- A phase II clinical trial platform utilizing total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002. (2016) (3)
- Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel (WP) or eribulin (E) followed by doxorubicin and cyclophosphamide (AC) in women with locally advanced HER2-negative breast cancer (LABC): NSABP FB-9. (2014) (3)
- Improved lymphocyte cytotoxicity against murine renal cell carcinoma. (1992) (3)
- Patient-reported neurotoxicity with FULV versus FLOX in patients with stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. (2016) (3)
- A phase II clinical trial platform for sensitization testing using total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002. (2019) (3)
- Abstract OT1-2-01: NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx) (2012) (3)
- Tamoxifen a nd C hemotherapy f or A xillary N ode-Negative, Estrogen R eceptor-Negativ e B reast C ancer: F indings F rom National S urgical A djuvant B reast a nd B owel P roject B -23 (2001) (3)
- NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC). (2012) (3)
- A comparison of two and three years of adjuvant tamoxifen. (1989) (3)
- NRG Oncology research opportunities within the new National Clinical Trials Network. (2014) (3)
- Abstract OT2-04-08: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze (2020) (3)
- Abstract S4-9: Comparing the Prediction of Chemotherapy Benefit in Patients with Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and a New Measure That Integrates Clinical and Pathologic Factors with the Recurrence Score (2010) (3)
- Use of letrozole after aromatase inhibitor-based therapy (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled phase 3 trial. (2018) (3)
- Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab (2018) (3)
- Overview docetaxel at the 2005 San Antonio Breast Cancer Symposium (2006) (2)
- Abstract P3-14-01: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis (2020) (2)
- Abstract S6-04: Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy (2016) (2)
- Comparative effectiveness of sphincter-sparing surgery (SSS) versus abdomino-perineal resection (APR) in rectal cancer: Patient-reported outcomes (PROs) from NSABP R-04. (2012) (2)
- Mucosal field change in colorectal cancer (1987) (2)
- The Impact of Radiation Therapy on Lymphedema Risk and the Agreement Between Subjective and Objective Lymphedema Measures: NSABP B-32 Secondary Data Analysis (2014) (2)
- The 12-Gene Colon Cancer Recurrence Score (RS) Predicts Recurrence in Stage II and III Colon Cancer Patients Treated with 5FU/LV (FU) and 5FU/LV + Oxaliplatin (FU + OX): Validation in NSABP C07 (2012) (2)
- NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab (2021) (2)
- Abstract OT2-3-02: NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx) (2013) (2)
- Phase II study to determine surgical conversion rate in patients receiving neoadjuvant mFOLFOX7 plus cetuximab for unresectable wild-type KRAS colorectal cancer with metastases confined to liver. (2010) (2)
- A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Updated results of NSABP C-10 with definitive survival analysis. (2013) (2)
- Predictive Factors for Positive Non-Sentinel Nodes Following a Positive Sentinel Node Biopsy: NSABP B-32. (2009) (2)
- Chemotherapy (CT) for isolated locoregional recurrence (ILRR) of breast cancer in ER-positive (ER+) and ER-negative (ER-) cohorts: Final analysis of the CALOR trial. (2017) (2)
- Statin polyp prevention trial in patients with resected colon cancer: NSABP protocol P-5. (2012) (2)
- P117 Exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): results of NSABP B-33 (2007) (2)
- Abstract P3-10-04: The fully validated NSABP/NRG 8-gene signature which predicted the degree of benefit in the adjuvant setting (B-31 and NCCTG N9831) associates with pCR in the neoadjuvant setting in NSABP clinical trial FB-7 (2019) (2)
- Chemosensitivity and stratification by a five monoclonal antibody IHC test in the NSABP B20 trial (2007) (2)
- Effect of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer after prior adjuvant therapy with an aromatase inhibitor (AI): NRG Oncology/NSABP B-42 (2017) (2)
- Cellular cytotoxicity and serum inhibition in normal mice following transfer of syngeneic tumor-sensitized cells. (1980) (2)
- Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence: Results of an accent meta-analysis of seven studies. (2019) (2)
- Abstract C46: NSABP FC-7: A phase Ib study evaluating neratinib (N) and cetuximab (Cmab) in patients (pts) with quadruple wild-type (quad wt) (KRAS/NRAS/BRAF/PI3KCA wt) metastatic colorectal cancer (mCRC) resistant to Cmab (2015) (2)
- Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess). (2017) (2)
- Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29. (2012) (2)
- Utilizing total neoadjuvant therapy (TNT) in rectal cancer: NRG-GI002, a phase II clinical trial platform. (2017) (2)
- INFLAMMATORY CELL INFILTRATE IN A RESPONDING METASTATIC NODULE AFTER ADOPTIVE TRANSFER OF IN VITRO SENSITIZED (IVS) T CELLS AND SYSTEMIC INTERLEUKIN-2 (1992) (2)
- Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: Results from NRG Oncology/NSABP C-07. (2016) (2)
- Effect of serial sectioning and immunohistochemistry (IHC) on sentinel lymph nodes (SLNs) on the false-negative rate (FNR) of SLN biopsy (SLNB): Results from NSABP B-32. (2011) (2)
- Cellular cytotoxicity and serum inhibition in normal mice following transfer of xenogeneic tumor-sensitized cells. (1979) (2)
- Quality of life in breast cancer patients receiving sentinel-node (SN) biopsy alone or with axillary dissection (AD): Results from NSABP Protocol B-32 (2008) (2)
- Abstract P3-12-01: Impact of treatment on quality of life (QOL) and menstrual history (MH) in the NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (2015) (2)
- Abstract OT2-02-03: NSABP FB-13: An assessment of the biological and clinical effects of palbociclib with ovarian suppression and letrozole in the neoadjuvant treatment of pts (pts) with premenopausal (preM) estrogen-receptor positive/HER2-negative primary breast cancer (2020) (2)
- Abstract PD2-1: Body mass index at diagnosis and breast cancer survival prognosis among clinical trial populations: Results from NSABP B-30, B-31, B-34, and B-38 (2013) (2)
- Abstract P5-06-02: Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC) (2020) (1)
- Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831 (2020) (1)
- Relationship between number of lymph node dissected and the risk of axillary/supraclavicular failure in patients with breast cancer treated by mastectomy and chemotherapy (+/- tamoxifen) without radiation: results from five NSABP trials (2002) (1)
- Abstract OT3-05-01: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze (2019) (1)
- The Study of Tamoxifen and Raloxifene (STAR): Change in patient-reported outcomes (PROs) after the end of treatment (2007) (1)
- Evaluation of outcomes over time (1998-2009) of patients (pts) with stage III colon cancer receiving adjuvant FOLFOX: Analysis of 7,230 patients from MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials in the ACCENT Database. (2018) (1)
- Rethinking the role of nodal status in TNM staging of node-positive breast cancer (2007) (1)
- P264 Predicting late distant recurrence risk in ER+ breast cancer after five years of tamoxifen (2015) (1)
- Correlation of levels of Akt phosphorylation at Ser473 with benefit from paclitaxel chemotherapy in NSABP B-28 patients with node-positive breast cancer. (2016) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP B-43. (2011) (1)
- Stapled Baker type anastomosis for low anterior resections. (1990) (1)
- Abstract 4064: Association of molecular signatures, mutations, and sTILs, with pCR in breast cancer patients in NRG Oncology/NSABP B-52 (2019) (1)
- Dose intensity comparison of African-American and white patients in NSABP breast treatment trials of postoperative doxorubicin and cyclophosphamide. (2006) (1)
- The Credentialing Process for the NSABP B-51/RTOG 1304 Phase 3 Randomized Clinical Trial (2014) (1)
- NRG-GI002: A phase II clinical trial platform for sensitization testing using total neoadjuvant therapy (TNT) in rectal cancer. (2018) (1)
- Provocative optimism in the treatment of early stage disease. (2005) (1)
- Multigene predictors developed on breast cancer cell lines to predict patient chemotherapy response: A validation study on the NSABP B-27 trial. (2011) (1)
- Abstract P6-07-06: Patterns of locoregional failure in the CALOR (Chemotheraphy as Adjuvant for Locally Recurrent Breast Cancer) Trial (2012) (1)
- Abstract S5-1: Prospective Outcomes for Patients with Micro-Metastases and Macro-Metastases In Sentinel Nodes: NSABP B-32 Sentinel Node Trial (2010) (1)
- An Update of the Credentialing Process for the NRG Oncology NSABP B-51 / RTOG 1304 Phase 3 Randomized Clinical Trial (2015) (1)
- DCIS: evidence from radomized trials (2003) (1)
- 478 Prognostic Significance of pAKT Plus Estrogen Receptor Status in Adjuvant Cytotoxic Treatment of Breast Cancer (2012) (1)
- Effect of axillary dissection for occult detected sentinel nodes metastases on survival: NSABP B-32. (2011) (0)
- IL-2 Adjuvant Therapy of Colorectal Cancer : the NSABP Experience (2006) (0)
- Prolonging Tamoxifen Therapy for Primary Breast Cancer (2020) (0)
- Comparison of self-reported outcomes with arm functional measurements in early breast cancer patients undergoing nodal biopsy in NSABP Protocol B-32 (2005) (0)
- CONSIDERATIONS IN THE DEVELOPMENT AND VALIDATION OF GENOMIC TESTS FOR CANCER RECURRENCE AND TREATMENT BENEFIT (2010) (0)
- Adjuvant Therapy for Breast Cancer: Where We Are, Where We're Headed (2008) (0)
- NSABP B-41, a randomized neoadjuvant trial: Genes and signatures associated with pathologic complete response (pCR). (2019) (0)
- Mammographic density and obesity as risk factors for invasive breast cancer following ductal carcinoma in situ (DCIS) (2003) (0)
- Abstract P2-16-26: Mixed invasive ductal and lobular carcinoma (IDC/L) behaves similarly to invasive lobular carcinoma (ILC) with regard to neoadjuvant chemotherapy response and metastatic dissemination (2020) (0)
- NSABP FC-10: Phase IB study of pembrolizumab in combination with premetrexed + oaliplatin in patients (pts) with chemo-refractory metastatic colorectal cancer (mCRC). (2020) (0)
- Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer: NSABP FR-2. (2019) (0)
- Abstract PS7-15: Mixed invasive ductal lobular carcinomas (mDLC) are clinically more similar to invasive lobular carcinoma (ILC) than to invasive ductal carcinoma (IDC) (2021) (0)
- Augmentation of cell mediated cytotoxicity (cmc) in tumor bearing mice following transfer of tumor sensitized spleen cells (tssc). Abstr. (1981) (0)
- Abstract P6-10-03: The contribution of common genetic variation to breast cancer risk among women receiving tamoxifen or raloxifene within the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and P-2 trials (2015) (0)
- Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor – Positive Early Breast Cancer (2019) (0)
- TAILORx Update (2019) (0)
- Session 6 Primary prevention of breast cancer II: Update of chemoprevention with tamoxifen, raloxifen and aromatase-inhibitors (2004) (0)
- Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08. (2021) (0)
- KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer (2019) (0)
- Should log odds of positive lymph node be incorporated into AJCC TNM breast cancer staging system (2008) (0)
- A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx): NSABP B-43. (2012) (0)
- Abstract 3407: Development of a chemokine signature identifying dMMR patients (pts) with poor prognosis (2019) (0)
- Abstract A201: Mutation profiling and prognostic value of BRAF, HRAS, KRAS, MET, NRAS, PIK3CA, KRASG12V in colon cancer: Results from NSABP C‐07 (2009) (0)
- Adoptive immunotherapy of murine mammary carcinoma using broadly cytotoxic cloned T lymphocytes. (1987) (0)
- A Pilot Clinical Trial to Assess Percutaneous Segmental Mastectomy in Women with Malignant Tumors < or = 1.0 Centimeter (1999) (0)
- Effect of prolonged Corynebacterium parvum and cyclophosphamide administration on spontaneously occurring metastases. (1975) (0)
- Fluoropyrimidines for the Adjuvant Treatment of Colorectal Cancer: The NSABP Experience (2002) (0)
- Title Cancer survivorship research : the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group Permalink (2009) (0)
- Abstract 4727: Breast cancer prevention and selective estrogen response modulators (SERMs): Pharmacogenomics and differential estrogen and SERM regulation of BRCA1 and BRCA2 expression (2011) (0)
- Outcomes over time (1998-2009) of stage II colon cancer patients (pts) receiving adjuvant FOLFOX: Pooled analysis of 1,122 pts in the ACCENT database. (2018) (0)
- A phase II clinical trial of ZD1839 (gefitinib) in combination with docetaxel as first-line treatment in patients with advanced breast cancer (2007) (0)
- P1-06-15: A Genomic Predictor Developed from Breast Cancer Cell Lines Predicts Both Disease-Free Survival and Overall Survival in Breast Cancer Patients Treated with Doxorubicin and Cyclophosphamide: A Collaborative Project of the NSABP and Precision Therapeutics. (2011) (0)
- The significance of regional lymph node cell mediated cytotoxicity in the response of a murine adenocarcinoma to chemoimmunotherapy. Abstr. (1983) (0)
- Tamoxi fen , Radiat ion Therapy , or Both for Prevent ion of Ips i la tera l Breast Tumor Recurrence Af ter Lumpectomy in Women With Invas ive Breast Cancers of One Cent imeter or Less (2002) (0)
- Fluoropyrimidines for the Adjuvant Treatment of Colorectal Cancer (2003) (0)
- 177PRECURRENCE SCORE AND QUANTITATIVE ER EXPRESSION PREDICTS LATE DISTANT RECURRENCE RISK IN ER+ BC AFTER FIVE YEARS OF TAMOXIFEN. (2014) (0)
- P39 13 TP – GEOMETRIC RESISTANCE AND VASCULAR ARCHITECTURE OF HUMAN TUMORS (1991) (0)
- Course announcement (2005) (0)
- Abstract P5-21-01: Effect of adjuvant systemic therapy in reducing rates of loco-regional recurrence in early-stage breast cancer: Results from nine NSABP randomized phase III trials (2015) (0)
- Tumor metastasis of mammary carcinoma to the lung reflected in an in vitro chemotaxis assay of bone marrow cells from c3h mice. Abstr. (1981) (0)
- Adjuvant Chemotherapy for Locoregional Recurrent Breast Cancer (2011) (0)
- P3-13-01: Boost Radiation Therapy Not of Value in Reducing IBTR of Invasive or Noninvasive Breast Cancers for Patients with DCIS: Results from the NSABP B-24 Trial. (2011) (0)
- Evaluation of disease-free survival (DFS) as a surrogate for overall survival (OS) in the adjuvant therapy of HER2-positive early breast cancer (EBC) calls for individual-patient data (IPD) (2017) (0)
- American Society of Colon and Rectal Surgeons 95th Annual Convention Podium and Poster Abstracts June 9–14, 1996 Seattle, Washington (1996) (0)
- Metastatic behavior of mixed invasive ductal lobular carcinoma (mIDC/ILC). (2020) (0)
- Abstract P5-17-01: A definition of a high-risk early-breast cancer population based on data from the collaborative trials in neoadjuvant breast cancer (CTNeoBC) meta-analysis (2013) (0)
- Benefit of oxaliplatin in stage III colon cancer according to IDEA risk groups: Analysis of MOSAIC and C-07 trials. (2020) (0)
- Abstract ML1: The Contribution of NSABP Clinical Trials to the Management of Early Breast Cancer (2016) (0)
- Editorial: Adjuvant chemotherapy in colorectal cancer. (1976) (0)
- Analysis of circulating tumour DNA for early relapse detection in stage III colorectal cancer after adjuvant chemotherapy (2019) (0)
- Reply to S. Mahesh (2012) (0)
- Reply to R. Glynne-Jones et al (2010) (0)
- Chemotherapy induced amenorrhea as an indicator of better survival in early breast cancer (2010) (0)
- Book reviews (2005) (0)
- Efficacy of Oxaliplatin on Overall and Disease-Free Survival (2008) (0)
- Breast cancer-specific survival (BCSS) in patients (pts) with nodenegative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world evidence study (2019) (0)
- Demographic characteristics and quality of life factors among the participants of the breast cancer prevention trial (1998) (0)
- Progress in carcinoma of the breast—Introduction (1985) (0)
- Cellular cytotoxicity in tumor-bearing mice after transfer of normal or tumor-sensitized lymphoid cells. (1980) (0)
- Abstract CT129: Association of the FCGR2A and FCGR3A genotypes with trastuzumab benefit in NSABP B-31 (2015) (0)
- The Use of Tramoxifen and Roloxifene for the Prevention of Breast Cancer (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Norman Wolmark?
Norman Wolmark is affiliated with the following schools:
- University of Vermont
- University of Kentucky
- University of Oxford
- Riken
- University of California, Los Angeles
- University of Chicago
- University of Siena
- National Taiwan University
- Yonsei University
- Baylor University
- McGill University
- University of British Columbia
- Allegheny University of the Health Sciences
- University of Edinburgh
- Oregon Health & Science University
- Queen Mary University of London
- University of Pittsburgh